Onco Actu du 28 septembre 2017

	1. Biologie
How do cancer cells release their “brakes” to allow division? [UNC] In the study, researchers described how a common signaling pathway in cancer cells – the PI3-kinase signaling pathway – helps to turn off one of the natural brakes on cell division.
	5. Traitements
High-precision radiotherapy for prostate cancer 'shows promise' [NHS Choices] This was an early-stage trial that aimed to investigate whether the treatment approach is safe and to get an idea of what doses may be suitable for assessment in further trials. Although it can give an indication of effectiveness, this was not the main aim of the study.
	5.12.2 Immunothérapies - CAR-T
Rubius names ex-GlaxoSmithKline VP as CMO as CAR-T rivals near clinic [FierceBiotech] Rubius produces its off-the-shelf cell therapies in bioreactors, making the supply chain notably less complex than those established by Novartis and Kite Pharma.
	5.12.5 Immunothérapies - Pharma
Merck adds real patient to 'TRU' Keytruda TV ad [FiercePharma] Donna was diagnosed with stage 4 non-small cell lung cancer more than a year ago, and in the new 90-second TV commercial, she talks about her journey with Keytruda after testing for high levels of PD-L1.
	5.12.7 Immunothérapies - vaccins
PPD to run first-in-human trial of Treos’ lead cancer vaccine [FierceBiotech] Besides the colorectal candidate, Treos said it had also completed preclinical development of six other cancer vaccines for the treatment of breast cancer, lung cancer, ovarian cancer, glioma, melanoma and leukemia.
	5.2 Pharma
Mateon cuts cancer combo test, costs as it refocuses efforts [FierceBiotech] Given the failure and what the company admits are its “limited resources,” the biotech is making severe cuts, removing 60% of its works since the beginning of the year, and with the remaining set of its senior management team taking a 50% cut in salary, effective immediately.
Mateon Therapeutics Announces Termination of Focus Study in Ovarian Cancer and Restructuring to Prioritize OXI4503 for AML [Mateon] All patients enrolled in the FOCUS study received either CA4P or placebo plus the current standard-of-care for platinum-resistant ovarian cancer: bevacizumab (Avastin®) and chemotherapy.
Small is big: Pharma’s R&D brain drain continues as GSK’s Chris Carpenter jumps to upstart Rubius [EndPoints] Their places in Big Pharma R&D are often filled by high-profile academic investigators. And that is starting to look like the great circle of drug R&D in this brave new world.
	5.2.3 Pharma - économie
Pharma's pricing pledges? Maybe they weren't such a good idea in the first place, experts say [FiercePharma] “I don’t see why anybody would give pledges because pledges are meant to be broken, and that just creates ill will,” Ken Kaitin, director of the Tufts Center for the Study of Drug Development.
	5.9.5 IASLC
Takeda to Feature ALUNBRIGTM (brigatinib) Data from Pivotal Phase 2 ALTA Trial at 18th World Conference on Lung Cancer [Takeda] Presentations Include Updated Trial Data and Results from Additional Analyses in Crizotinib-Refractory ALK+ Non-Small Cell Lung Cancer.
Bristol-Myers Squibb: Advancing Research Across Thoracic Cancers with New Data at IASLC 18th World Conference on Lung Cancer [BMS] Presentations will include late-breaking data in malignant pleural mesothelioma, clinical and real-world evidence in Opdivo in previously treated advanced non-small cell lung cancer (NSCLC), as well as research on Opdivo-based combinations in advanced NSCLC and patient-reported outcomes in advanced small cell lung cancer (SCLC).
	6. Lutte contre les cancers
Can Heart Disease Shed Light on Cancer? [NY Times] What are the chances that one molecule, sitting at one corner of the immune response, acts as a switch for two utterly different diseases?
	6.4 Médico-éco
JAMA Forum: The High Costs of Unnecessary Care [JAMA] Unnecessary care is expensive. In a 2013 report, the Institute of Medicine argued that “unnecessary services” added $210 billion to health care spending in the United States, making it the single biggest contributor to waste.
	6.7.2 Applis
Apple, J&J join FDA program to fast-track digital health apps [FierceBiotech] The ways companies collect postmarket reports are of particular interest to the FDA given this data will be critical to safety in a environment with reduced upfront regulatory requirements.